Chronic subdural haematoma: time to rationalize treatment?

Area of Science:

• Neurosurgery
• Neurology
• Clinical Medicine

Background:

• Chronic subdural hematoma (CSH) is a frequent neurosurgical diagnosis.
• Existing literature presents varied evidence on CSH incidence, pathogenesis, and treatment.
• Despite its prevalence, definitive answers regarding optimal management remain elusive.

Discussion:

• Current management approaches for CSH are diverse, often influenced by surgeon preference.
• There is a notable lack of high-level evidence, such as Class I randomized controlled trials, guiding treatment decisions.
• The heterogeneity in treatment strategies highlights the need for more standardized, evidence-based protocols.

Key Insights:

• CSH presents significant challenges due to persistent unanswered questions in its management.
• Personal preferences heavily influence current treatment options, indicating a need for objective data.
• Evidence synthesis reveals a critical gap in robust clinical trials for CSH.

Outlook:

• Future research should prioritize Class I randomized studies to establish evidence-based guidelines for CSH treatment.
• Rationalizing management strategies through rigorous scientific inquiry is essential.
• Advancing the understanding and treatment of CSH will improve patient outcomes.